CN109568349A - 一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 - Google Patents
一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 Download PDFInfo
- Publication number
- CN109568349A CN109568349A CN201910006513.6A CN201910006513A CN109568349A CN 109568349 A CN109568349 A CN 109568349A CN 201910006513 A CN201910006513 A CN 201910006513A CN 109568349 A CN109568349 A CN 109568349A
- Authority
- CN
- China
- Prior art keywords
- solution
- sterilizing
- minutes
- many kinds
- compound targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- 238000001035 drying Methods 0.000 title claims abstract description 17
- 238000007710 freezing Methods 0.000 title claims abstract description 17
- 230000008014 freezing Effects 0.000 title claims abstract description 17
- 239000000126 substance Substances 0.000 title claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 39
- 108090000790 Enzymes Proteins 0.000 claims abstract description 39
- 239000006041 probiotic Substances 0.000 claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 33
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 17
- 229920001661 Chitosan Polymers 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 17
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 17
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims abstract description 17
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 239000000661 sodium alginate Substances 0.000 claims abstract description 17
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 17
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 17
- 229920002907 Guar gum Polymers 0.000 claims abstract description 8
- 239000001110 calcium chloride Substances 0.000 claims abstract description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 8
- 239000000665 guar gum Substances 0.000 claims abstract description 8
- 235000010417 guar gum Nutrition 0.000 claims abstract description 8
- 229960002154 guar gum Drugs 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract description 3
- 238000000576 coating method Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 107
- 230000001954 sterilising effect Effects 0.000 claims description 65
- 239000000843 powder Substances 0.000 claims description 42
- 239000000725 suspension Substances 0.000 claims description 36
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 15
- 229930092411 Swietenocoumarin D Natural products 0.000 claims description 15
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 230000008901 benefit Effects 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 abstract description 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract description 2
- 239000003124 biologic agent Substances 0.000 abstract description 2
- 229960002713 calcium chloride Drugs 0.000 abstract description 2
- 235000011148 calcium chloride Nutrition 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,属于生物制剂包埋领域,本发明提供肠溶多层包埋,以α‑环糊精与麦芽糊精为第一层包埋,经冷冻干燥后粉碎170目,瓜尔胶,海藻酸钠与氯化钙,经冷冻干燥后粉碎120目为第二层包埋,最后以可溶性大豆多糖,微晶纤维素与壳聚糖,经冷冻干燥后粉碎80‑100目,成为第三层包埋,利用三层壁材,使内包裹的益生菌、活性酶物质等穿过胃酸环境,到达肠道中定植,做到靶向释放出益生菌、活性酶物质。
Description
技术领域
本发明涉及生物制剂包埋领域,具体是指一种复合靶向肠溶多种物质包埋真空冷冻干燥技术。
背景技术
益生菌在人身体内十分重要,菌群平衡构成了我们肠道健康,菌群失衡导致腹泻、便秘等,一旦菌群失衡,额外补充益生菌就尤为重要,通过口服益生菌补充菌群效果直接明显,但胃部酸性环境对活性益生菌伤害明显,酶是一种具有活性功能的蛋白质,它是由活细胞形成并且帮助执行生命中无数的生物化学反应和过程的一些复杂结构物质,在人体内有无数各种各样酶系去完成人体新陈代谢过程,包埋技术可以很好的保护菌种到达肠胃,提高效率和效果。
发明内容
本发明要解决的技术问题是,针对以上问题提供一种提供益生菌穿过胃酸环境,到达肠道定植的方法。
为解决上述技术问题,本发明提供的技术方案为:一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,所述复合靶向肠溶包埋真空冷冻干燥技术,包括以下步骤:
1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置灭菌α-环状糊精溶液;
3)配置灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以(600-800):1比例混合均匀;
8)配置灭菌海藻酸钠溶液;
9)配置灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:(5-15)比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置灭菌可溶性大豆多糖溶液;
14)配置灭菌微晶纤维素溶液;
15)配置灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以(20-50):1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
进一步的,所述灭菌α-环状糊精溶液为α-环状糊精8%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌麦芽糊精溶液为麦芽糊精6%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌海藻酸钠溶液为海藻酸钠(7-10)%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌氯化钙溶液为氯化钙5-8%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌可溶性大豆多糖溶液为可溶性大豆多糖5%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌微晶纤维素溶液为微晶纤维素5%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌壳聚糖溶液为壳聚糖3%溶液,经121℃灭菌25分钟制备而成。
本发明与现有技术相比的优点在于:利用三层壁材,使内包裹的益生菌、活性酶物质等穿过胃酸环境,到达肠道中定植,做到靶向释放出益生菌、活性酶物质,能够让益生菌穿过胃酸环境,到达肠道定植,菌种为活性菌种、真空冷冻干燥最大程度保留菌种活,三层包埋、三次冻干,利用三次粉碎目数的不同,物理上最大程度保证包埋效果。
具体实施方式
本发明在具体实施时,一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,所述复合靶向肠溶包埋真空冷冻干燥技术,包括以下步骤:
1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置灭菌α-环状糊精溶液;
3)配置灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以(600-800):1比例混合均匀;
8)配置灭菌海藻酸钠溶液;
9)配置灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:(5-15)比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置灭菌可溶性大豆多糖溶液;
14)配置灭菌微晶纤维素溶液;
15)配置灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以(20-50):1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
进一步的,所述灭菌α-环状糊精溶液为α-环状糊精8%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌麦芽糊精溶液为麦芽糊精6%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌海藻酸钠溶液为海藻酸钠(7-10)%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌氯化钙溶液为氯化钙5-8%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌可溶性大豆多糖溶液为可溶性大豆多糖5%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌微晶纤维素溶液为微晶纤维素5%溶液,经121℃灭菌25分钟制备而成。
进一步的,所述灭菌壳聚糖溶液为壳聚糖3%溶液,经121℃灭菌25分钟制备而成。
本发明的工作原理:一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,属于生物制剂包埋领域,本发明提供肠溶多层包埋,以α-环糊精与麦芽糊精为第一层包埋,经冷冻干燥后粉碎170目,瓜尔胶,海藻酸钠与氯化钙,经冷冻干燥后粉碎120目为第二层包埋,最后以可溶性大豆多糖,微晶纤维素与壳聚糖,经冷冻干燥后粉碎80-100目,成为第三层包埋,利用三层壁材,使内包裹的益生菌、活性酶物质、活性酶物质等穿过胃酸环境,到达肠道中定植,做到靶向释放出益生菌、活性酶物质。
实施例:
实施例一:1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置α-环状糊精8%溶液,经121℃灭菌25分钟,得到灭菌α-环状糊精溶液;
3)配置麦芽糊精6%溶液,经121℃灭菌25分钟,得到灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以600:1比例混合均匀;
8)配置海藻酸钠7%溶液,经121℃灭菌25分钟,得到灭菌海藻酸钠溶液;
9)配置氯化钙5-8%溶液,经121℃灭菌25分钟,得到灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:5比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置可溶性大豆多糖5%溶液,经121℃灭菌25分钟,得到灭菌可溶性大豆多糖溶液;
14)配置微晶纤维素5%溶液,经121℃灭菌25分钟,得到灭菌微晶纤维素溶液;
15)配置壳聚糖3%溶液,经121℃灭菌25分钟,得到灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以20:1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
实施例二:1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置α-环状糊精8%溶液,经121℃灭菌25分钟,得到灭菌α-环状糊精溶液;
3)配置麦芽糊精6%溶液,经121℃灭菌25分钟,得到灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以800:1比例混合均匀;
8)配置海藻酸钠10%溶液,经121℃灭菌25分钟,得到灭菌海藻酸钠溶液;
9)配置氯化钙5-8%溶液,经121℃灭菌25分钟,得到灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:15比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置可溶性大豆多糖5%溶液,经121℃灭菌25分钟,得到灭菌可溶性大豆多糖溶液;
14)配置微晶纤维素5%溶液,经121℃灭菌25分钟,得到灭菌微晶纤维素溶液;
15)配置壳聚糖3%溶液,经121℃灭菌25分钟,得到灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以50:1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
实施例三:1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置α-环状糊精8%溶液,经121℃灭菌25分钟,得到灭菌α-环状糊精溶液;
3)配置麦芽糊精6%溶液,经121℃灭菌25分钟,得到灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以720:1比例混合均匀;
8)配置海藻酸钠8%溶液,经121℃灭菌25分钟,得到灭菌海藻酸钠溶液;
9)配置氯化钙5-8%溶液,经121℃灭菌25分钟,得到灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:11比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置可溶性大豆多糖5%溶液,经121℃灭菌25分钟,得到灭菌可溶性大豆多糖溶液;
14)配置微晶纤维素5%溶液,经121℃灭菌25分钟,得到灭菌微晶纤维素溶液;
15)配置壳聚糖3%溶液,经121℃灭菌25分钟,得到灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以37:1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
以上对本发明及其实施方式进行了描述,这种描述没有限制性,以上所示的也只是本发明的实施方式之一,实际的结构并不局限于此。总而言之如果本领域的普通技术人员受其启示,在不脱离本发明创造宗旨的情况下,不经创造性的设计出与该技术方案相似的结构方式及实施例,均应属于本发明的保护范围。
Claims (8)
1.一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述复合靶向肠溶包埋真空冷冻干燥技术,包括以下步骤:
1)将益生菌或活性酶物质粉充分混合,粉碎200目;
2)配置灭菌α-环状糊精溶液;
3)配置灭菌麦芽糊精溶液;
4)将步骤2)和步骤3)溶液充分混合;
5)将步骤4)混合溶液与益生菌粉或活性酶粉混合,通过高压均质机形成悬浊液;
6)将步骤5)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎170目,得到第一层包埋益生菌、活性酶物质粉;
7)将步骤6)所得菌粉与瓜尔胶粉以(600-800):1比例混合均匀;
8)配置灭菌海藻酸钠溶液;
9)配置灭菌氯化钙溶液;
10)将步骤7)与步骤8)以1:(5-15)比例混合形成悬浊液;
11)将步骤9)溶液倒入步骤10)溶液,通过高压均质机获得悬浊液;
12)将步骤11)经真空冷冻干燥冻干,水分≤10%,粉碎120目,得到第二层包埋益生菌、活性酶物质粉;
13)配置灭菌可溶性大豆多糖溶液;
14)配置灭菌微晶纤维素溶液;
15)配置灭菌壳聚糖溶液;
16)将步骤13)、14)和15)均匀混合液以(20-50):1与步骤12)混合,通过高压均质机获得悬浊液;
17)将步骤16)悬浊液经真空冷冻干燥冻干,水分≤10%,粉碎80-100目,得到第三层包埋益生菌、活性酶物质粉。
2.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌α-环状糊精溶液为α-环状糊精8%溶液,经121℃灭菌25分钟制备而成。
3.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌麦芽糊精溶液为麦芽糊精6%溶液,经121℃灭菌25分钟制备而成。
4.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌海藻酸钠溶液为海藻酸钠(7-10)%溶液,经121℃灭菌25分钟制备而成。
5.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌氯化钙溶液为氯化钙5-8%溶液,经121℃灭菌25分钟制备而成。
6.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌可溶性大豆多糖溶液为可溶性大豆多糖5%溶液,经121℃灭菌25分钟制备而成。
7.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌微晶纤维素溶液为微晶纤维素5%溶液,经121℃灭菌25分钟制备而成。
8.根据权利要求1所述的一种复合靶向肠溶多种物质包埋真空冷冻干燥技术,其特征在于:所述灭菌壳聚糖溶液为壳聚糖3%溶液,经121℃灭菌25分钟制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006513.6A CN109568349A (zh) | 2019-01-04 | 2019-01-04 | 一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006513.6A CN109568349A (zh) | 2019-01-04 | 2019-01-04 | 一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109568349A true CN109568349A (zh) | 2019-04-05 |
Family
ID=65915952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910006513.6A Pending CN109568349A (zh) | 2019-01-04 | 2019-01-04 | 一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109568349A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494601A (zh) * | 2020-04-02 | 2020-08-07 | 安杰利(重庆)生物科技有限公司 | 一种过瘤胃的肠溶性抗菌肽颗粒及制备方法 |
CN112715890A (zh) * | 2020-12-25 | 2021-04-30 | 贵州统之源食品有限公司 | 一种固定化泡菜发酵剂及其应用 |
CN115251392A (zh) * | 2021-04-29 | 2022-11-01 | 内蒙古伊利实业集团股份有限公司 | 一种活性益生菌及其包埋方法以及在常温液体产品中的应用 |
CN115428950A (zh) * | 2022-07-27 | 2022-12-06 | 陕西师范大学 | β-胡萝卜素双重包埋微粒及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1916161A (zh) * | 2006-09-08 | 2007-02-21 | 肖雯娟 | 一种肠道益生菌包埋保护方法 |
CN104783124A (zh) * | 2014-01-21 | 2015-07-22 | 四川亿生元科技有限公司 | 益生元食用盐及其制备方法 |
WO2017137496A1 (en) * | 2016-02-10 | 2017-08-17 | Fundacion Tecnalia Research & Innovation | Multilayer probiotic microcapsules |
-
2019
- 2019-01-04 CN CN201910006513.6A patent/CN109568349A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1916161A (zh) * | 2006-09-08 | 2007-02-21 | 肖雯娟 | 一种肠道益生菌包埋保护方法 |
CN104783124A (zh) * | 2014-01-21 | 2015-07-22 | 四川亿生元科技有限公司 | 益生元食用盐及其制备方法 |
WO2017137496A1 (en) * | 2016-02-10 | 2017-08-17 | Fundacion Tecnalia Research & Innovation | Multilayer probiotic microcapsules |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494601A (zh) * | 2020-04-02 | 2020-08-07 | 安杰利(重庆)生物科技有限公司 | 一种过瘤胃的肠溶性抗菌肽颗粒及制备方法 |
CN111494601B (zh) * | 2020-04-02 | 2022-04-22 | 安杰利(重庆)生物科技有限公司 | 一种过瘤胃的肠溶性抗菌肽颗粒及制备方法 |
CN112715890A (zh) * | 2020-12-25 | 2021-04-30 | 贵州统之源食品有限公司 | 一种固定化泡菜发酵剂及其应用 |
CN112715890B (zh) * | 2020-12-25 | 2024-01-09 | 贵州统之源食品有限公司 | 一种固定化泡菜发酵剂及其应用 |
CN115251392A (zh) * | 2021-04-29 | 2022-11-01 | 内蒙古伊利实业集团股份有限公司 | 一种活性益生菌及其包埋方法以及在常温液体产品中的应用 |
CN115428950A (zh) * | 2022-07-27 | 2022-12-06 | 陕西师范大学 | β-胡萝卜素双重包埋微粒及其制备方法和应用 |
CN115428950B (zh) * | 2022-07-27 | 2024-05-17 | 陕西师范大学 | β-胡萝卜素双重包埋微粒及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109568349A (zh) | 一种复合靶向肠溶多种物质包埋真空冷冻干燥技术 | |
Razavi et al. | Microencapsulating polymers for probiotics delivery systems: Preparation, characterization, and applications | |
Liu et al. | Recent trends and applications of polysaccharides for microencapsulation of probiotics | |
Asgari et al. | Polymeric carriers for enhanced delivery of probiotics | |
CN110025638B (zh) | 壳聚糖‐羧甲基纤维素钠层层自组装益生菌微囊及其制备 | |
CA2538676C (en) | Probiotic storage and delivery | |
Khorasani et al. | Starch-and carboxymethylcellulose-coated bacterial nanocellulose-pectin bionanocomposite as novel protective prebiotic matrices | |
EP2155768B1 (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
CN106418547A (zh) | 一种益生菌微胶囊及其制备方法 | |
CN112544978B (zh) | 一种可在肠道定点释放的微胶囊包埋的益生菌及其制备方法 | |
CHACKOSHIAN et al. | Improvement of probiotic survival in fruit juice and under gastrointestinal conditions using pectin-nanochitin-nanolignocellulose as a novel prebiotic gastrointestinal-resistant matrix | |
US20220000793A1 (en) | Biomass-based encapsulating material for protection of probiotic activity and an encapsulating method | |
CN101401638A (zh) | 一种食用菌合生元微胶囊的制备方法 | |
NZ539900A (en) | Nutraceuticals and method of feeding aquatic animals | |
Varankovich et al. | Survival of probiotics in pea protein-alginate microcapsules with or without chitosan coating during storage and in a simulated gastrointestinal environment | |
CN110367542B (zh) | 一种在肠道中缓慢释放的益生菌微胶囊及其制备方法 | |
CN116115652A (zh) | 一种多糖包埋益生菌及其制备方法与药物 | |
KR20180070485A (ko) | 안정성이 증진된 유산균 및 이의 제조방법 | |
Chotiko et al. | Three protective agents for pectin-rice bran capsules for encapsulating Lactobacillus plantarum | |
CN111436614A (zh) | 基于香菇可溶性膳食纤维的益生菌递送微胶囊及制备方法 | |
JP2002320473A (ja) | 蛋白質及び多糖類を利用した二重コーティング乳酸菌原末の製造方法 | |
Martins et al. | Xylo-oligosaccharide microparticles with synbiotic potential obtained from enzymatic hydrolysis of sugarcane straw | |
KR101707551B1 (ko) | 유산균 생균 제제를 함유한 초콜릿의 제조 방법 | |
Nezamdoost-Sani et al. | A comprehensive review on the utilization of biopolymer hydrogels to encapsulate and protect probiotics in foods | |
Sun et al. | Advances in probiotic encapsulation methods to improve bioactivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190405 |
|
RJ01 | Rejection of invention patent application after publication |